Posted by Michael Wonder on 01 Feb 2023
Simcere’s COVID-19 pill goes on sale in China at less than half the price of Pfizer’s Paxlovid
31 January 2023 - The retail price of Simcere Pharmaceutical’s orally taken COVID-19 treatment, which was only approved to go to market in China two days ago, has been set at 40% of the cost of US pharma giant Pfizer’s Paxlovid tablet.
A course of Xiannuoxin, China's first homegrown 3CL protease inhibitor pill to be approved for sale, will cost CNY750 (USD111), the Beijing Municipal Public Security Bureau said yesterday. Paxlovid, which is also a protease inhibitor, retails for CNY1,890 a box.
